Stay updated on ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Sign up to get notified when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.

Latest updates to the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page
- Check4 days agoChange DetectedAdded Study Status entries dated 2026-01-12 and 2026-01-09 with Revision: v3.3.4; removed the 2025-10-03 entry and Revision: v3.3.3 from the history.SummaryDifference0.4%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedFooter updated to show Revision: v3.3.3, and references to HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.2%

- Check54 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the Record History; these are site revision notes and do not affect trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved the government funding/operating status notice from the page.SummaryDifference0.6%

- Check75 days agoChange DetectedThe page history shows additional Study Status updates across multiple versions, indicating changes in the trial's recruitment and overall status over time.SummaryDifference0.1%

- Check104 days agoChange DetectedUpdated operating status notice, current date, new study status, and new software revision (v3.2.0); removed older revision (v3.1.0) and an earlier date (2025-08-13).SummaryDifference13%

Stay in the know with updates to ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.